BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting
BeiGene, a biotechnology company, will present clinical data on its BTK inhibitor BRUKINSA and anti-PD-1 antibody tislelizumab at the 62nd ASH Annual Meeting from December 5-8, 2020. Highlights include an oral presentation titled Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma. Additionally, a symposium on BTK Inhibitors in CLL is co-sponsored by BeiGene. Publication numbers for presentations are provided, detailing various trials and studies.
- Presentation of multiple studies at a major medical conference, enhancing visibility.
- Potential for positive impact on treatment outcomes with new clinical data.
- None.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its BTK inhibitor BRUKINSA® (zanubrutinib) and non-clinical data on its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and four posters at the 62nd American Society for Hematology (ASH) Annual Meeting, taking place virtually on December 5-8, 2020.
BeiGene is co-sponsoring a satellite symposium entitled Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes, to be held on Friday, December 4 at 3:00 p.m. PT; registration for the symposium can be accessed at https://events.clinicaloptions.com/oncology/event-list/event/?id=a95f3d53-49d8-ea11-80f9-005056943d50.
Oral Presentation:
Title: |
Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial |
|
Publication #: |
339 |
|
Session Title: |
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Clinical studies in Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia |
|
Date and Time: |
Sunday, December 6, 2020 at 10:15 a.m. PT |
|
Presenter: |
Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Australia |
Poster Presentations:
Title: |
Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial |
|
Publication #: |
2940 |
|
Session Title: |
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III |
|
Date: |
Monday, December 7, 2020 at 7:00 a.m. PT |
|
Presenter: |
Gang An, M.D., Ph.D., Chinese Academy of Medical Sciences, Blood Diseases Hospital, China |
Title: |
Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib |
|
Publication #: |
2947 |
|
Session Title: |
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III |
|
Date: |
Monday, December 7, 2020 at 7:00 a.m. PT |
|
Presenter: |
Mazyar Shadman, M.D., MPH, Fred Hutchinson Cancer Research Center, University of Washington |
Title: |
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial |
|
Publication #: |
1306 |
|
Session Title: |
642. CLL: Therapy, excluding Transplantation: Poster I |
|
Date: |
Saturday, December 5, 2020 at 7:00 a.m. PT |
|
Presenter: |
Jennifer R. Brown, M.D., Ph.D., Dana-Farber Cancer Institute |
Title:
|
Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action |
|
Publication #: |
1116 |
|
Session Title: |
622. Lymphoma Biology—Non-Genetic Studies: Poster I |
|
Date: |
Saturday, December 5, 2020 at 7:00 a.m. PT |
|
Presenter: |
Yuqin Song, M.D., Ph.D., Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), China |
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
